Hjgh. Mulder et al., Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasly (REGRESS trial), AM J CARD, 86(7), 2000, pp. 742-746
Citations number
27
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
The Regression Growth Evaluation Statin Study (REGRESS) is a placebo-contro
lled multicenter study designed to assess the effect of 2-year treatment wi
th pravastatin on the progression and regression of angiographically docume
nted coronary artery disease. One of the secondary end points was the occur
rence of 2-year restenosis in the percutaneous transluminal coronary angiop
lasty (PTCA) block. We randomly assigned eligible patients to receive prava
statin 40 mg once daily or placebo. The end point was the percent diameter
stenosis of the target lesion at 24 months, as assessed by (semi)quantitati
ve coronary angiography, Two hundred twenty-one patients underwent schedule
d PTCA, which was considered successful in 201 patients, One hundred sevent
y-eight patients underwent angiographic restudy (89%). The patients in the
pravastatin group (n = 109) and placebo group (n = 112) were similar at bas
eline. Percent diameter stenosis before angioplasty was 78 +/- 14% (mean +/
- SD) in the pravastatin group and 80 +/- 14% in the placebo group (p = 0.4
6), At follow-up, the percent diameter stenosis was 32 +/- 23% in the prava
statin group and 45 +/- 29% in the placebo group (p < 0.001), Clinical rest
enosis was significantly lower in the pravastatin group (7%) compared with
the placebo group (29%) (p < 0.001), Risk reduction for all events was 58%,
We conclude that treatment with pravastatin reduces 2-year clinical and an
giographic restenosis, (C) 2000 by Excerpta Medico, Inc.